Launch of GLUBES® Combination Orally Disintegrating Tablet, a Rapid-acting Insulin Secretagogue and Agent for Postprandial Hyperglycemia

Kissei Pharmaceutical Co., Ltd. (chairman and CEO: Mutsuo Kanzawa; "Kissei") announced today that the GLUBES^® Combination OD Tab., which is the new orally disintegrating dosage form of the GLUBES^® Combination Tab. (generic name: mitiglinide calcium hydrate/voglibose), will be launched on June 14, 2019 in Japan, for the treatment of diabetes.

GLUBES^® Combination Tab. is an oral combination drug comprising the rapid-acting insulin secretagogue mitiglinide, which was created by Kissei, and the postprandial hyperglycemia agent voglibose. This product was launched in July 2011 for the treatment of type 2 diabetes. GLUBES^® Combination Tab. rapidly stimulates insulin secretion (mitiglinide) and improves postprandial hyperglycemia (voglibose). With the effect of these two different mechanisms of action, the combination drug is expected to improve postprandial blood glucose levels and lower HbA1c more than single agent therapy.

The GLUBES^® Combination OD Tablet is a new dosage form and the first combination OD tablet developed for the treatment of diabetes. This dosage form will allow patients to consume the combination drug with or without water, as it rapidly disintegrates in the oral cavity.

With the addition of GLUBES^® Combination OD Tablet to our product lineup, we aim to further contribute to the treatment of diabetes and offer a new therapeutic option to patients.


<Product Summary of GLUBES^® Combination OD Tablet>

Brand Name:
GLUBES^® Combination OD Tab.

Generic Name:
Mitiglinide calcium hydrate/voglibose

Indications:
Type 2 diabetes

Dosage and Administration:

The recommended dose for adults is a single dose of 10 mg mitiglinide calcium hydrate and 0.2 mg voglibose administered orally three times daily, immediately before meals.

NHI price:
GLUBES^® OD Combination Tab. single-dose tablet: ¥47.70

Date of Drug Price Listing: June 14, 2019

Date of Launch in Japan: June 14, 2019

Manufactured and Distributed by:

KISSEI PHARMACEUTICAL CO., LTD.